, respectively (P trend < 0.0001). Analysis using fractional polynomials indicated a non-linear association. The association was stronger in women never using menopausal hormone therapy (HT) compared with past and current users (P interaction < 0.0001). Our findings strongly suggest a protective effect for post-menopausal breast cancer through a better vitamin D supply as characterized by serum 25(OH)D measurement, with a stronger inverse association in women with low serum 25(OH)D concentrations (<50 nM).
Introduction
Epidemiological and experimental studies suggest an inverse association between vitamin D and cancer of different sites, including breast cancer (1) (2) (3) (4) (5) (6) . Most epidemiological studies have assessed the effects of dietary intake only, although endogenous production after sun exposure is the main source of vitamin D (6) . Both vitamin D from diet and endogenous production is converted via two consecutive hydroxylation steps to 25- Although not biologically active, there is overall agreement that 25(OH)D is the appropriate biomarker with which to measure vitamin D status in humans. In contrast to 1,25(OH) 2 D, 25(OH)D is not tightly regulated and better reflects vitamin D stores obtained from both sunlight exposure and ingested vitamin D over longer periods (11) (12) (13) (14) . Recent studies have demonstrated that conversion to the biologically active form of vitamin D 1,25(OH) 2 D also occurs in extrarenal tissues such as colon, prostate and breast (15) (16) (17) . In addition, a recent cell study reported expression of CYP27B1, the enzyme that converts 25(OH)D to active 1,25(OH) 2 D, in mammary cells as well as growth inhibition of mammary cells by 25(OH)D, thus linking vitamin D status to breast cancer risk (18) .
Data from epidemiologic studies assessing the association between dietary intake of vitamin D and breast cancer risk have been inconclusive (5, (19) (20) (21) (22) (23) (24) (25) . Thus far, only four studies have assessed the relationship between serum vitamin D metabolites [25(OH)D or 1,25 (OH) 2 D)] and breast cancer risk (2, 4, 26, 27) . Of two small hospitalbased case-control studies, one found a significantly inverse association for 25(OH)D and breast cancer risk (4) , whereas the other study revealed no association for 25(OH)D but an inverse association for 1,25(OH) 2 D (27) . A case-control study nested in a voluntary health check up showed no association between 1,25(OH) 2 D and breast cancer risk (26) . To date, the largest case-control study including 701 cases nested in the Nurses' Health Study (NHS) (2) reported a non-significant decrease in breast cancer risk both with higher serum 25(OH)D and with 1,25(OH) 2 D concentrations.
To our knowledge, the present study including 1394 cases is by far the largest population-based case-control study assessing the relationship of serum 25(OH)D concentrations and breast cancer risk in post-menopausal women. Because estrogens are known to increase concentrations of vitamin D-binding protein, VDR and serum 25(OH)D (28-34), we additionally examined effect modification by risk factors including hormone-related variables such as menopausal hormone therapy (HT) and number of pregnancies.
Materials and methods

Study population and data collection
We used data from a large population-based case-control study (MARIE study, Mamma Carcinoma Risk factor Investigation) carried out in two regions in Germany, the city of Hamburg and the Rhein-Neckar-Karlsruhe (R-N-K) region. The study was approved by the ethics committees of both the University of Heidelberg and the University of Hamburg and conducted in accordance with the Declaration of Helsinki. All study participants gave informed consent. Cases were eligible if they had a histologically confirmed primary invasive or in situ breast cancer diagnosed between 01 January 2001 and 30 September 2005 in Hamburg and between 01 August 2002 and 31 July 2005 in the R-N-K region. Further inclusion criteria were age between 50 and 74 and being a resident of one of the study regions. Cases were identified through frequent monitoring of hospital admissions, surgery schedules and pathology records. Clinical and pathological characteristics of the patients were abstracted from hospital and pathology records. Of the 5970 eligible patients who could be contacted, 3919 (65.6%) participated, whereas 2051 (34.4%) declined participation or did not respond to invitation letters.
Two controls per case were randomly selected from lists of residents provided by population registries and frequency matched by year of birth and study region to the cases. Of the 17 093 controls who met the inclusion criteria, 7421 (43.4%) participated, 7521 (44.0%) refused to participate and 2151 (12.6%) did not respond.
All participants were interviewed by trained personnel to obtain information on sociodemographic factors, anthropometric measures, data on lifetime HT exposure, including information on timing and duration, type, dose and brand name of HT, and other potential breast cancer risk factors. An alphabetical list with photographic depictions of .300 HT products prescribed in Germany over the past 35 years was presented to women as a memory aid recalling their HT history. In addition, participants reported their dietary habits during the past 12 months with a self-administered validated 176 items' food frequency questionnaire (35 
Data analysis
Women were defined as post-menopausal if they reported their last natural menstrual bleeding at least 12 months before the reference date, a bilateral oophorectomy or cessation of menses due to radiation or chemotherapy. In addition, women .55 years with unclear menopausal status due to hysterectomy or hormone use were also considered post-menopausal (since the 90th percentile for age at menopause for women with natural menopause was 55 years). Women under age 55 with unclear menopausal status and women who were clearly pre-menopausal were excluded from the analysis. A total of 3464 invasive or in situ breast cancer cases and 6657 controls, of which 1559 cases and 3008 controls came from the R-N-K region, were classified as postmenopausal. For this analysis, we identified 1400 post-menopausal cases from the R-N-K region for whom we had blood samples (90% of the cases from the study region) and randomly selected 1400 post-menopausal controls from the same study region with matching on time of blood collection in four categories (January-March, April-June, July-September and October-December) and year of birth (continuous). After exclusion of hemolytic serum samples, our final study population consisted of 1394 post-menopausal cases and 1365 postmenopausal controls.
We assessed the association of serum 25(OH)D and post-menopausal breast cancer risk by means of logistic regression with stratification by year of birth (continuous) and time of blood collection (four categories). Odds ratio (OR) estimates and their 95% confidence intervals (CIs) were calculated assessing 25(OH)D concentration both as continuous (per 10 nM increment) and as categorical variable divided into five categories (,30, 30-45, 45-60, 60-75, !75 nM). This categorization closely corresponds to the classification into quintiles according to the distribution in the control group. We present OR estimates adjusted for age at menopause (,47, 47-51, 52-55, !56, unknown), body mass index (BMI) (,22.5, 22.5-25, 25-30, !30 kg/m2), education level (low, middle, high), first-degree family history of breast cancer (yes, no, unknown), history of benign breast disease (yes, no), number of pregnancies (!28th week) (0, 1, 2, !3), age at menarche (,12, 12-14, !15), breastfeeding history (ever, never), total number of mammograms (0, 1-4, 5-9, !10, unknown), smoking status (never, past, current) and use of menopausal HT (never, past, current). Women reporting HT use for 3 months before the reference date were considered 'never' users and women with .3 months were considered 'ever' users. Among the ever users, women were defined as 'current' users of HT if they reported use within 6 months before the reference date; otherwise they were defined as 'past' users. Adjustment on type of menopause, type of HT, age at first birth, alcohol consumption, contraceptive use, physical activity, dietary intake of calcium and dietary intake of vitamin D did not affect the OR estimates substantially and were therefore not included in the fully adjusted models. Test for linear trend was performed using the median values in each category as an ordinal variable. To further examine dose-response relation and non-linearity of the log OR function for predictive 25(OH)D concentrations, we used the method of fractional polynomials (36) . The continuous 25(OH)D variable was entered into the multivariate logistic regression model via a set of defined transformations [
3 and log(x)], allowing a maximum of two terms (including the untransformed variable) in the model. The function that best fitted the data was selected on the basis of the À2 log likelihood of the respective model. We additionally fitted the multivariate logistic regression models with restricted cubic splines for 25(OH)D concentration treated as a continuous variable (37) . We specified four knot points at 25(OH)D concentrations of 9.7, 36, 51.5 and 70.7 representing the minimum, the 25th, 50th and 75th percentiles in the control group, respectively. Other knot points were also specified but did not change the shape of the OR function.
We assessed effect modification by testing for multiplicative interaction. We included an interaction term of the continuous variable of interest [25(OH)D] and potential interaction variables in the fully adjusted model and evaluated statistical significance with the likelihood ratio test. Differences in cases and controls were evaluated with the v 2 test. All tests were two sided and considered to be statistically significant if P 0.05. All statistical analyses were carried out using the statistical software SAS 9.1 (SAS Institute, Cary, NC).
Results
The mean age of cases and controls was 63.6 and 63.5 years, respectively. Characteristics, including sociodemographic variables and main risk factors for breast cancer, of the 1394 post-menopausal cases and 1365 post-menopausal controls are shown in Table I . Cases and controls differed significantly with respect to age at menopause, family history of breast cancer in at least one first-degree relative, benign breast disease history, number of pregnancies, breastfeeding history, age at menarche, number of mammograms and use of menopausal HT (Table I) .
Median serum concentration of 25(OH)D was 44.9 and 51.5 nM in cases and controls, respectively (P , 0.0001). We found a significant inverse association between serum concentration of 25 (Table II) . We further examined the shape of the risk function using fractional polynomials and found a non-linear association between the log OR and the 25(OH)D concentration (P non-linearity 5 0. There was a good fit between the curve and the OR estimates of the categorical analysis. Using restricted cubic spline regression, the shape of the risk function was similar, but model fit was inferior compared with the model using fractional polynomials.
Following previous reports on the interaction between the estrogen and the vitamin D endocrine system, we evaluated effect modification by use of HT. Median serum 25(OH)D concentrations were higher in women currently using HT compared with past or never users. However, these differences were more prominent in cases than in controls (Table III) (Table III) . The interaction between 25(OH)D concentration and use of HT was statistically significant (P interaction , 0.0001) and independent of the type of HT used (estrogen-only or combined estrogen-progestin therapy). The effect modification by HT use also did not differ by estrogen receptor (ER) or progesterone receptor (PR) status of the tumor. (Table IV) .
The association between 25(OH)D concentration and breast cancer risk was not significantly modified by age, smoking status, age at menarche, age at menopause, BMI, alcohol, family history of breast S.Abbas et al.
cancer, breastfeeding history, history of benign breast disease, physical activity or dietary intake of calcium. In addition, no modification by ER or PR status of the tumor or combinations of both was observed. We further examined the association of serum 25(OH)D and breast cancer risk within strata of dietary vitamin D intake. The association remained inverse and no statistical interaction was observed. In addition, dietary intake was not correlated with serum 25(OH)D (r 5 0.03, P 5 0.14).
Median difference between time of diagnosis and time of blood collection in cases was 66 days. In a sensitivity analysis, we evaluated potential effects of diagnosis or cancer therapy on circulating (14) . Recently, a case-control study found lower levels of 1,25(OH) 2 D but not 25(OH)D in breast cancer patients (38) . However, this study was very small and no risk estimates were reported.
Results regarding the association between vitamin D metabolites and breast cancer risk are not easy to compare because of different metabolite levels in the study populations and reference groups used for calculating relative risks. In our study, median serum 25(OH)D 
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concentrations of 44.9 and 51.5 nM for cases and controls, respectively, were comparable with recently published data from the German National Health Survey for women in this age range (39) . However, 25(OH)D concentrations were relatively low compared with other studies in the USA and the UK reporting mean concentrations of .80 nM (2,4). We therefore repeated our analysis calculating OR estimates for breast cancer risk comparing women with concentrations .100 nM 25(OH)D to women with concentrations ,50 nM 25(OH)D, which is comparable with the categorization in the NHS (2). The observed inverse association was considerably stronger in our study population compared with that found in the NHS [OR (95% CI) Our findings of a non-linear relationship between 25(OH)D concentrations and the log OR for breast cancer using fractional polynomials are of special interest. In our study population, the protective effect was strongest in women with low 25(OH)D concentrations (,50 nM) and was reduced substantially with higher 25(OH)D concentration. These are important public health findings for women in low 25(OH)D concentration ranges and indicate subgroups where vitamin D supplementation may be most relevant for breast cancer prevention. Due to the low 25(OH)D concentrations in our study population, we were able to provide important additional information to further understand the dose-response relationship of vitamin D and breast cancer risk.
We found a statistically significant modification of the association of breast cancer risk and serum 25(OH)D concentrations with a stronger effect in women never having used HT as compared with HT users. Accordingly, results from the NHS showed some evidence for a stronger effect in non-HT users, although power was low for their comparisons (2) . In women using HT, taking oral contraceptives or with increased endogenous estrogen levels, higher concentrations of vitamin D metabolites have been reported (32, 33, 41, 42) . The underlying mechanisms include the estrogen-induced activation of renal 1a-hydroxylase, inhibition of 24-vitamin D hydroxylase and the upregulation of the VDR resulting in increased serum concentrations and activity of 25(OH)D and 1,25(OH) 2 D (33,41,43,44). We also found higher 25(OH)D serum concentrations in women currently using HT compared with past or never users, and this difference was not attributable to differences in age, BMI, physical activity or other known breast cancer risk factors. Serum 25(OH)D concentrations in women never using HT were significantly lower in cases than in controls (P , 0.0001), whereas no significant case-control differences were observed in women currently using HT. We hypothesize that HT may induce an increase in 25(OH)D only below a certain threshold level of 25(OH)D (median: 37.3 and 47.6 nM for cases and controls never using HT, respectively), resulting in differential effects in cases and controls in our study population and in effect modification by HT on the association of 25(OH)D with breast cancer risk. In line with this hypothesis, use of HT was significantly associated with 25(OH)D using a linear regression model in women with low serum 25(OH)D concentrations (,50 nM, b 5 2.2, P 5 0.004) but not in women with high serum concentrations (.50 nM, b 5 À2.2, P 5 0.21). To our knowledge, there is, however, no data biologically supporting this threshold hypothesis.
We also found a stronger effect of 25(OH)D on breast cancer risk in women with increasing number of pregnancies. Parity is known to be associated with changes in sex hormone level resulting in a potential lower lifetime estrogen exposure (45, 46) . Cell studies on the interaction of estrogens, anti-estrogens and 1,25(OH) 2 D in tumor cell lines have been conducted. In cell studies, 1,25(OH) 2 D has been shown to be considerably more anticarcinogenic in combination with anti-estrogens (47, 48) . In addition, in the presence of estradiol, 1,25(OH) 2 D has been shown to stimulate proliferation at low doses and inhibit proliferation at higher doses, whereas in a non-estrogen environment, only anti-proliferative effects have been observed (48) . Therefore, both, the interaction of 25(OH)D with use of HT and with the number of pregnancies, could be explained by interactions with the estrogen metabolism, i.e. a lower lifetime exposure to estrogens resulting in a potential stronger anticarcinogenic effect of vitamin D. However, the complex regulation of vitamin D in the human body and its interactions with the estrogen metabolism in breast cancer cells deserve further investigation.
We further analyzed whether the effect of vitamin D on breast cancer differed by receptor status of the tumor and did not find differential effects. Recent data from the NHS suggest an inverse association for ERÀ/PRÀ, but not for ERþ/PRþ and ERþ/PRÀ tumors, Our study may have methodological limitations due to the retrospective case-control design. We are aware that a cancer diagnosis may change dietary or behavioral habits (less dietary intake of vitamin D, less sun exposure), which may influence 25(OH)D concentrations. Nevertheless, short-term changes in diet or behavioral habits are less likely to influence serum concentration because the half-life of 25(OH)D is rather long (2-3 weeks), the correlation between dietary vitamin D and serum 25(OH)D in this study was low (r 5 0.03) and plasma levels of 25(OH)D are fairly consistent over time (51) . Although a notable change in 25(OH)D concentration after chemotherapeutic treatment was not observed in two studies (52, 53) , cancer therapy following diagnosis may affect circulating 25(OH)D concentration. However, the sensitivity analysis excluding patients ,6 months between diagnosis and blood collection showed no notable change in the risk estimates.
Selection bias due to the participation rate of cases and controls is also unlikely to have biased our results in terms of 25(OH)D status. Information collected via short questionnaire from subjects who refused participation indicated that the study participants were better educated and reported hormone use more frequently than nonparticipants. However, these differences between study participants and non-participants answering the short questionnaire only were similarly observed both for cases and controls and therefore unlikely to have biased our results. Unfortunately, no information on 25(OH)D status-, diet-or vitamin D-related variables like outdoor activity was available for the non-participants with short questionnaire information.
Finally, we address the concern of possible measurement errors with respect to 25(OH)D status. Several reports emphasize the measurement variation introduced by different assays and different laboratories (14, 54, 55) . Nevertheless, in the international Vitamin D Quality Assessment Scheme, which monitors the performance of vitamin D assays, the IDS enzyme immunoassay used in our study gave comparable results to the gold standard high-performance liquid chromatography method (56) . In addition, intra-and interassay variation in 25(OH)D measurement as well as the average absolute deviation from the mean between two duplicate samples were very low in our analysis, reassuring the validity of the biomarker measurement. 
In summary, we found a significant inverse association between serum 25(OH)D concentration and post-menopausal breast cancer risk. In addition, the relationship was non-linear, suggesting a stronger effect in women with low 25(OH)D concentrations as compared with women with higher concentrations. Use of HT and number of pregnancies were identified as modifiers of the association between serum 25(OH)D and breast cancer risk. The association was stronger in women who had never used HT compared with women with past or current use and in women with increasing number of pregnancies; however, these findings need confirmation in further studies. Our findings strongly suggest a protective effect for post-menopausal breast cancer risk through a better vitamin D supply as characterized by measurement of serum 25(OH)D.
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